Iloperidone, asenapine and lurasidone: a primer on their current status

Bibliography

• Heckers S, Berretta S. Schizophrenia. In: Tarazi FI, Schetz JA, editors. Neurological and psychiatric disorders: from bench to bedside. Humana Press; Totowa, NJ: 2005. p. 111-29
   Google Scholar
• Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008;26:149-62
   PubMed Web of Science ®Google Scholar
• O’Carroll R. Cognitive impairment in schizophrenia. Adv Psychiatr Treat 2000;6:161-8
   Google Scholar
• Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York: 2005. p. 461-500
   Google Scholar
• Stahl SM. Stahl's essential psychopharmacology. 3rd edition. Cambridge Univ Press; NY: 2008
   Google Scholar
• Stahl SM. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011
   Google Scholar
• Kane J, Honigfeld G, Singer J, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99(Suppl):S18-27
   Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746-54
   PubMed Web of Science ®Google Scholar
• Brunello N, Masotto C, Steardo L, New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995;13:177-213
   PubMed Web of Science ®Google Scholar
• Raja M. Clozapine safety, 35 years later. Curr Drug Saf 2011;6:164-84
   PubMedGoogle Scholar
• Leung JY, Barr AM, Procyshyn RM, Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012;135:113-22
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71
   PubMed Web of Science ®Google Scholar
• Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust NZ J Psychiatry 2008;42:369-81
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-9
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
   PubMed Web of Science ®Google Scholar
• Kongsamut S, Roehr JE, Cai J, Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317:417-23
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-14
   PubMed Web of Science ®Google Scholar
• Barr AM, Powell SB, Markou A, Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 2006;51:457-65
   PubMed Web of Science ®Google Scholar
• Volpi S, Potkin SG, Malhotra AK, Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70(6):801-9
   PubMed Web of Science ®Google Scholar
• Shahid M, Walker GB, Zorn SH, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73
   PubMed Web of Science ®Google Scholar
• Ghanbari R, El Mansari M, Shahid M, Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha2-adrenergic and D2 receptors in the rat brain. Eur Neuropsychopharmacol 2009;19:177-87
   PubMed Web of Science ®Google Scholar
• Frånberg O, Wiker C, Marcus MM, Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29
   PubMed Web of Science ®Google Scholar
• Marston HM, Young JW, Martin FD. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 2009;206:699-714
   PubMed Web of Science ®Google Scholar
• Snigdha S, Idris N, Grayson B, Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 2011;214:843-53
   PubMed Web of Science ®Google Scholar
• Elsworth JD, Groman SM, Jentsch JD, Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 2012;62:1442-52
   PubMed Web of Science ®Google Scholar
• Frånberg O, Marcus MM, Ivanov V, Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009;204:251-64
   PubMed Web of Science ®Google Scholar
• Huang M, Li Z, Dai J, Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008;33:2934-45
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008;198:103-11
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Choi YK, Gardner M, Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-20
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010;24:341-8
   PubMed Web of Science ®Google Scholar
• Choi YK, Wong EH, Henry B, Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-10
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81
   PubMed Web of Science ®Google Scholar
• Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs 2008;17:61-75
   PubMed Web of Science ®Google Scholar
• Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs 2000;9:2935-43
   PubMed Web of Science ®Google Scholar
• Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:553-60
   PubMed Web of Science ®Google Scholar
• Stahl SM. Iloperidone. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011. p. 267-71
   Google Scholar
• Sedek G, Wolfgang CD. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. Presented at American Psychiatric Association Annual Meeting; 27 May 2007; San Diego, CA
   Google Scholar
• Product Information Saphris® (asenapine) sublingual tablets. Initial US approval: 2009
   Google Scholar
• Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today 2009;45:865-76
   PubMed Web of Science ®Google Scholar
• Stahl SM. Asenapine. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011b. p. 59-63
   Google Scholar
• Peeters PAM, Bockbrader H, Spaans E, Asenapine pharmacokinetics: influence of hepatic and renal impairment [abstract NR4-081]. 161st Amer Psychiatric Assoc; 3 – 8 May, Washington DC; 2008
   Google Scholar
• Product Information Latuda® (lurasidone). Initial US approval: 2010
   Google Scholar
• Chiu YY, Preskorn S, Sarubbi D, Effect of food on lurasidone absorption (Poster). Presented at the NCDEU meeting; Boca Raton, FL; 2010
   Google Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-26
   PubMed Web of Science ®Google Scholar
• Stahl SM. Lurasidone. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011. p. 337-42
   Google Scholar
• Product Information Fanapt® (iloperidone). Initial US approval: 2009
   Google Scholar
• Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialized second-generation antipsychotic. Int J Clin Pract 2009;63:1237-48
   PubMed Web of Science ®Google Scholar
• Sonovion News Release. Latuda® (Lurasidone HCl) updated with expanded dosing range providing added flexibility for the treatment of patients with schizophrenia. May 5, 2012
   Google Scholar
• Corbett R, Griffiths L, Shipley JE. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 1997;3:120-47
   Google Scholar
• Potkin SG, Litman RE, Torres R, Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
   PubMed Web of Science ®Google Scholar
• Citrome L, Meng X, Hochfeld M, Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol 2012;27:24-32
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500
   PubMed Web of Science ®Google Scholar
• Kane JM, Zhao J, Cohen M, Efficacy and safety of asenapine in patients with acute schizophrenia [abstract 290]. 23rd Amer Psychiatric Nurses Assoc; 7 – 10 October; Charleston, SC; 2009
   Google Scholar
• Mackle M, Snow-Adami L, Zhao J, Double-blind placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia [abstract P.3.c.057]. 22nd Cong Eur Coll Neuropsychopharmacol; 12 – 16 September; Istanbul, Turkey; 2009
   Google Scholar
• Buchanan RW, Panagides J, Zhao J, Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012;32:36-45
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Alphs L, Cohen M, Treatment of mania in bipolar I disorder: placebo- and olanzapine-controlled trials of asenapine [abstract P2.e.012]. 20th Congr Eur Coll Neuropsychopharmacol; 13 – 17 October; Vienna, Austria; 2007
   Google Scholar
• McIntyre RS, Panagides J, Alphs L, Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501004). Biol Psychiatry 2007;61(S 8):S222-3
   Google Scholar
• McIntyre RS, Cohen M, Zhao J, A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-86
   PubMed Web of Science ®Google Scholar
• Szegedi A, Calabrese JR, Stet L, Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55
   PubMed Web of Science ®Google Scholar
• Ogasa M, Boylan M, Phillips D, Efficacy of lurasidone (SM-13496) in the treatment of schizophrenia: results of two phase 2, placebo-conrolled studies. Eur Neuropsychopharmacol 2005;15:S522-3
   Google Scholar
• Phillips D, Ogasa M, Severs J, Efficacy of lurasidone in schizophrenia: results of a phase 2, placebo-controlled study. Schizophr Bull 2007;33:572-3
   Google Scholar
• Loebel A, Cucchiaro J, Ogasa M. Efficacy of lurasidone in schizophrenia: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010;13(Suppl 1):217
   PubMedGoogle Scholar
• Meltzer HY, Cucchiaro J, Silva R, Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled Study. Am J Psychiatry 2011;168:957-67
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, Lurasidone in the treatment of acute schizophrenia: Results of the double-blind, placebo-controlled, 6-week, Pearl 3 trial [abstract no NR6-38]. 164th Annual Meeting of the American Psychiatric Association; 14 – 18 May 2011; Honolulu, HA
   Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:829-36
   PubMed Web of Science ®Google Scholar
• Chapel S, Hutmatcher M, Haig G, Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. J Clin Psychopharmacol 2009;49:1297-308
   Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind study [abstract no NR6-36]. 165th Annual Meeting of the American Psychiatric Association; 5 – 9 May 2012; Philadelphia, PA
   Google Scholar
• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-60
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Faure C, Lambás-Señas L, Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275-88
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, Lurasidone monotherapy for the treatment of bipolar I depression: Results of a 6-week, double-blind, placebo-controlled study [abstract no NR4-58]. 165th Annual Meeting of the American Psychiatric Association; 5 – 9 May 2012; Philadelphia, PA
   Google Scholar
• Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
   PubMed Web of Science ®Google Scholar
• Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-35
   PubMed Web of Science ®Google Scholar
• Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009;88:17-31
   PubMed Web of Science ®Google Scholar
• Shelton RC, Osuntokun O, Heinloth AN, Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, Novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
   PubMed Web of Science ®Google Scholar
• Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;13:1027-38
   PubMed Web of Science ®Google Scholar